Business Wire

Svante and Tenaska Forge Collaboration to Deliver Fully Integrated Carbon Capture and Storage Solutions

16.1.2025 16:03:00 EET | Business Wire | Press release

Share

Svante Technologies Inc. (Svante), a leading innovator in carbon capture and removal technology, and Tenaska, a prominent CO2 transportation and sequestration service provider, have signed a Memorandum of Understanding (MOU) to collaborate on delivering cost-effective, integrated solutions for industrial carbon capture and storage (CCS). This collaboration represents a significant step toward addressing global industrial emissions and advancing the decarbonization of many industrial sectors, including pulp & paper, cement, steel, oil & gas, and more.

Under the terms of the non-exclusive MOU, Svante and Tenaska will combine their technology and services to provide end-to-end CCS value chain solutions to select customers. Svante’s cutting-edge solid sorbent-based carbon capture technology will facilitate efficient, environmentally responsible CO2 capture, while Tenaska will provide regional planning and infrastructure for CO2 transportation and storage. Tenaska is advancing a platform of mid- and early-stage projects in strategic locations across the United States, with Class VI permit applications filed for nearly 20 injection wells across multiple states.

Together, the companies aim to simplify the path to decarbonization for industrial emitters worldwide.

Key Objectives of the Collaboration:

  1. Integrated Carbon Management Solutions:
    • Svante will focus on capturing CO2 emissions at industrial facilities, including related processes such as CO2 compression, conditioning, and liquefaction.
    • Tenaska will manage CO2 transportation and sequestration, ensuring safe, secure, permanent storage deep underground.
  2. North America-wide Outreach and Customer Engagement:
    • The joint initiative will actively promote carbon capture and storage to industrial emitters across North America, offering tailored solutions to meet diverse needs.
  3. Innovative Project Development:
    • The collaboration will identify and assess commercially viable opportunities for CCS, leveraging the combined technical and operational expertise of both organizations.

Leadership Quotes:

“This collaboration is well aligned with Svante’s mission to make carbon capture accessible for industries worldwide,” said Matt Stevenson, Chief Revenue Officer of Svante. “By combining our technology with Tenaska’s extensive experience in CO2 transportation and storage, we can offer end-to-end solutions that accelerate the transition to a net-zero future.”

“Recognizing the synergies with our CCS development platform, Tenaska is proud to work with Svante to advance innovative solutions for carbon management,” said Bret Estep, Vice President, Tenaska Development. “Together, we aim to provide industrial customers with the tools and confidence to achieve their decarbonization goals.”

A Vision for the Future

The Svante-Tenaska collaboration underscores a shared commitment to providing business solutions that help industrial sectors reduce carbon emissions. By offering integrated, efficient, and scalable CCS solutions, the companies aim to unlock new opportunities for industries to meet their sustainability targets while maintaining operational excellence.

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.

About Tenaska

Consistently ranked among Forbes’ List of America’s Largest Private Companies, Tenaska is a leading energy company with business operations that span the energy value chain. Tenaska Marketing Ventures (TMV) and Tenaska Power Services Co. (TPS) are among the largest natural gas and electric power marketing companies in North America. The company has an operating fleet of 7,460 megawatts (MW) of natural gas and renewable generating facilities and throughout its history has developed, managed and/or operated approximately 22,000 MW of natural gas-fueled and renewable generation. Tenaska is actively developing 10 carbon sequestration projects capable of storing more than 50 million metric tons of CO2 per year, multiple natural gas-fueled generation projects and a development services portfolio of more than 35,000 MW of solar, wind, energy storage and green hydrogen projects. Tenaska seeks investment opportunities to allocate its capital into generation assets nationwide. For more information, visit www.tenaska.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116961790/en/

Contacts

Media Contacts:
Svante:
Colleen Nitta
Director of Marketing and Communications
604-970-2813
cnitta@svanteinc.com

Tenaska:
Timberly Ross
Senior Director, Community Relations
402-691-9517
tross@tenaska.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye